IL128141A0 - Tetrahydroquinoline derivatives as eaa antagonists - Google Patents

Tetrahydroquinoline derivatives as eaa antagonists

Info

Publication number
IL128141A0
IL128141A0 IL12814197A IL12814197A IL128141A0 IL 128141 A0 IL128141 A0 IL 128141A0 IL 12814197 A IL12814197 A IL 12814197A IL 12814197 A IL12814197 A IL 12814197A IL 128141 A0 IL128141 A0 IL 128141A0
Authority
IL
Israel
Prior art keywords
tetrahydroquinoline derivatives
eaa antagonists
eaa
antagonists
tetrahydroquinoline
Prior art date
Application number
IL12814197A
Other languages
English (en)
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of IL128141A0 publication Critical patent/IL128141A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL12814197A 1996-08-17 1997-08-14 Tetrahydroquinoline derivatives as eaa antagonists IL128141A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9617305.9A GB9617305D0 (en) 1996-08-17 1996-08-17 Heterocyclic compounds
PCT/EP1997/004440 WO1998007704A1 (en) 1996-08-17 1997-08-14 Tetrahydroquinoline derivatives as eaa antagonists

Publications (1)

Publication Number Publication Date
IL128141A0 true IL128141A0 (en) 1999-11-30

Family

ID=10798623

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12814197A IL128141A0 (en) 1996-08-17 1997-08-14 Tetrahydroquinoline derivatives as eaa antagonists

Country Status (34)

Country Link
US (1) US6479488B1 (cs)
EP (1) EP0922034B1 (cs)
JP (1) JP4108129B2 (cs)
KR (1) KR100552864B1 (cs)
CN (1) CN1131214C (cs)
AP (1) AP877A (cs)
AR (1) AR008296A1 (cs)
AT (1) ATE221052T1 (cs)
AU (1) AU724473B2 (cs)
BR (1) BR9711311B1 (cs)
CA (1) CA2264118C (cs)
CO (1) CO4900066A1 (cs)
CZ (1) CZ296250B6 (cs)
DE (1) DE69714265T2 (cs)
DK (1) DK0922034T3 (cs)
EA (1) EA001704B1 (cs)
ES (1) ES2181030T3 (cs)
GB (1) GB9617305D0 (cs)
HU (1) HU225797B1 (cs)
ID (1) ID18095A (cs)
IL (1) IL128141A0 (cs)
IS (1) IS4953A (cs)
MY (1) MY116952A (cs)
NO (1) NO312241B1 (cs)
NZ (1) NZ333812A (cs)
PE (1) PE107098A1 (cs)
PL (1) PL194532B1 (cs)
PT (1) PT922034E (cs)
SI (1) SI0922034T1 (cs)
TR (1) TR199900336T2 (cs)
TW (1) TW449582B (cs)
WO (1) WO1998007704A1 (cs)
YU (1) YU6799A (cs)
ZA (1) ZA977326B (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9929037D0 (en) 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
AU2002359875B2 (en) * 2001-12-28 2009-01-08 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
RU2336879C2 (ru) * 2003-01-23 2008-10-27 Акадиа Фармасьютикалз Инк. Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20060233843A1 (en) * 2003-02-19 2006-10-19 Conn P J Treatment of psychosis with a muscarinic m1 receptor ectopic activator
JP2007534656A (ja) * 2003-12-22 2007-11-29 アカディア ファーマシューティカルズ,インコーポレーテッド ムスカリンアゴニストとしてのアミノ置換ジアリール[a,d]シクロヘプテン類似体および精神神経疾患の治療方法
US20050282800A1 (en) * 2004-04-01 2005-12-22 Bo-Ragnar Tolf Method of synthesis and isolation of solid N-desmethylclozapine and crystalline forms thereof
KR101136183B1 (ko) 2005-07-22 2012-04-17 모찌다 세이야쿠 가부시끼가이샤 신규 헤테로시클리덴 아세트아미드 유도체
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
EP1966229B1 (en) 2005-09-12 2015-10-21 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (dmso) or related compounds, or odors associated with same
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
US9427419B2 (en) 2005-09-12 2016-08-30 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (DMSO)
US20070105836A1 (en) * 2005-10-31 2007-05-10 Lars Pettersson Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
US9855212B2 (en) 2009-10-30 2018-01-02 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (DMSO) or DMSO and methylsulfonylmethane (MSM) formulations to treat infectious diseases
EP2763676B1 (en) 2011-10-03 2019-12-25 The University of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69029668T2 (de) 1989-03-08 1997-08-07 Merck Sharp & Dohme Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten
DE69622731T2 (de) 1995-09-29 2003-02-20 Glaxosmithkline S.P.A., Verona Tetrahydrochinoline als nmda antagonisten

Also Published As

Publication number Publication date
PT922034E (pt) 2002-12-31
US6479488B1 (en) 2002-11-12
DE69714265D1 (de) 2002-08-29
NZ333812A (en) 2000-07-28
BR9711311B1 (pt) 2009-01-13
HU225797B1 (en) 2007-09-28
ID18095A (id) 1998-02-26
NO312241B1 (no) 2002-04-15
PL194532B1 (pl) 2007-06-29
GB9617305D0 (en) 1996-09-25
AR008296A1 (es) 1999-12-29
NO990723L (no) 1999-04-14
PE107098A1 (es) 1999-01-15
TW449582B (en) 2001-08-11
AU724473B2 (en) 2000-09-21
ES2181030T3 (es) 2003-02-16
EA199900121A1 (ru) 1999-10-28
AU4551897A (en) 1998-03-06
CA2264118C (en) 2008-06-17
BR9711311A (pt) 1999-08-17
SI0922034T1 (en) 2003-02-28
AP877A (en) 2000-09-27
KR100552864B1 (ko) 2006-02-20
CA2264118A1 (en) 1998-02-26
CO4900066A1 (es) 2000-03-27
AP9901459A0 (en) 1999-03-31
DK0922034T3 (da) 2002-11-18
YU6799A (sh) 2000-03-21
HUP9903108A3 (en) 2004-04-28
ZA977326B (en) 1999-02-15
IS4953A (is) 1999-01-22
PL331562A1 (en) 1999-07-19
DE69714265T2 (de) 2003-03-06
CN1131214C (zh) 2003-12-17
CZ296250B6 (cs) 2006-02-15
MY116952A (en) 2004-04-30
EA001704B1 (ru) 2001-06-25
ATE221052T1 (de) 2002-08-15
CN1227544A (zh) 1999-09-01
WO1998007704A1 (en) 1998-02-26
EP0922034B1 (en) 2002-07-24
TR199900336T2 (xx) 1999-04-21
KR20000068172A (ko) 2000-11-25
JP2001508031A (ja) 2001-06-19
NO990723D0 (no) 1999-02-16
EP0922034A1 (en) 1999-06-16
CZ52999A3 (cs) 1999-07-14
JP4108129B2 (ja) 2008-06-25

Similar Documents

Publication Publication Date Title
IL143782A0 (en) Quinoline derivatives
HK1036618A1 (en) Quinoline derivatives
IL140346A0 (en) Quinoline derivatives
IL128141A0 (en) Tetrahydroquinoline derivatives as eaa antagonists
CY2505B1 (en) Quinoline derivatives as nk3 antagonists
IL113844A0 (en) Quinoline derivatives
ZA97913B (en) Substituted quinazolines derivatives
HK1024917A1 (en) Substituted 3-cyano quinolines
HUP0103634A3 (en) Quinoline derivatives
IL127432A0 (en) Substituted benzimidazole derivatives
HK1034079A1 (en) Tetrahydroquinoline derivatives as glycine antagonists
GB9404378D0 (en) Quinoline derivatives
ZA954269B (en) Quinoline derivatives
GB9402275D0 (en) Quinoline derivatives
GB9413150D0 (en) Quinoline derivatives
EG24161A (en) Carbostyril derivatives
HU9701548D0 (en) 1-carba-(dethia)-cephalosporin derivatives
HU9603342D0 (en) Quinoline derivatives as leukotriene antagonists
SI1086093T1 (sl) Derivati tetrahidrokinolina kot antagonisti glicina
GB9711030D0 (en) Quinoline leukrotriene antagonists
IL126806A0 (en) Quinoline derivatives
GB9402306D0 (en) Quinoline derivatives
GB9413937D0 (en) Quinoline derivatives

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees